Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$515.92 5.21 (1.00)%

High 522.00 Low 513.40 Volume 617,665 Market Cap 53.85B
07/21/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Jul 21

    Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis

    Read on
  • Jul 13

    Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q2 2017 Earnings Conference Call
    Aug 3, 2017 | 8:30 AM ET

Events & Presentations

NASDAQ REGN

$515.92 5.21 (1.00)%

High 522.00 Low 513.40 Volume 617,665 Market Cap 53.85B
07/21/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information